Gedea Biotech strengthens IP portfolio with new European patent for treating infections with GDL
PRESS RELEASE Gedea Biotech today announced that European patent no. 3 691 625 has entered into force, further strengthening Gedea’s intellectual property protection for pHyph in Europe, until 2038. The patent covers the use of glucono delta-lactone (GDL) for the treatment of bacterial vaginosis…
Gedea Biotech strengthens IP portfolio with new US patent for vaginal formulation
PRESS RELEASE Gedea Biotech today announced that the company has been granted a US patent for its vaginal formulation (patent no. 12,496,288). The patent marks an important step for Gedea Biotech in protecting the product on the US market and is expected to be of high strategic value for future…